Zariana Nikolova

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

Charles D. Blanke, George D. Demetri, Margaret von Mehren et al. · Journal of Clinical Oncology · 2008 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Jane F. Apperley, Martine Gardembas, Junia V. Melo et al. · New England Journal of Medicine · 2002 · 631 citations · Full text

Medicine, Hematology, Molecular Genetics +16

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Grant A. McArthur, George D. Demetri, A. van Oosterom et al. · Journal of Clinical Oncology · 2005 · 481 citations

Medicine, Oncology, Pathology +17

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

George D. Demetri, Yanfeng Wang, Elisabeth Wehrle et al. · Journal of Clinical Oncology · 2009 · 401 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)

Michael C. Heinrich, Grant A. McArthur, George D. Demetri et al. · Journal of Clinical Oncology · 2006 · 316 citations

Medicine, Oncology, Pharmacology +16